Metabolomic and biochemical changes in the plasma and liver of toxic milk mice model of Wilson disease

• Published in: Journal of pharmaceutical and biomedical analysis 2024-08, Vol.246, p.116255-116255, Article 116255
• Main Authors: Liu, Qiao, Wu, Xiaoyuan, Liu, Cuicui, Wang, Ni, Yin, Fengxia, Wu, Huan, Cao, Shijian, Zhao, Wenchen, Wu, Hongfei, Zhou, An
• Format: Article
• Language: English
• Subjects: Animals; Arachidonic Acid - metabolism; Copper - metabolism; Disease Models, Animal; Hepatolenticular Degeneration - metabolism; Liver - metabolism; Male; Metabolic indicators; Metabolomics - methods; Mice; Milk - metabolism; Oxidative Stress; Pathogenesis; Untargeted metabolomics; Wilson Disease
• ISSN: 0731-7085; 1873-264X
• DOI: 10.1016/j.jpba.2024.116255

Wilson disease (WD) is an inherited disorder characterized by abnormal copper metabolism with complex pathological features. Currently, this mechanism of copper overload-induced hepatic injury remains unclear. In this study, male toxic milk (TX) mice were selected as experimental subjects. Copper levels and biochemical indices were measured by atomic absorption spectroscopy (AAS) and kits. Liver tissue ultrastructure was observed by hematoxylin-eosin (H&E), sirius red staining and transmission electron microscopy. Plasma and liver metabolic profiles of TX mice were characterized by untargeted metabolomics. In addition, the expression of enzymes related to arachidonic acid metabolism in liver tissue was detected by Western blotting. The results showed the excessive copper content, concomitant oxidative stress, and hepatic tissue structural damage in TX mice. Seventy-eight metabolites were significantly different in WD, mainly involved in the metabolism of arachidonic acid, glycerophospholipids, sphingolipids, niacin and nicotinamide, and phenylalanine. Furthermore, the arachidonic acid metabolic pathway is an important pathway involved in WD metabolism. The level of arachidonic acid in the liver of TX mice was significantly lower (p < 0.01) compared to the control group. The expression of cytoplasmic phospholipase A2 (cPLA2) and arachidonic acid 12-lipoxygenase (ALOX12), related to the arachidonic acid metabolic pathway, was significantly different in the liver of TX mice (p < 0.01). Modulation of the arachidonic acid metabolic pathway could be a potential therapeutic strategy to alleviate WD symptoms. •Copper accumulation and excretion disorders occurs in the WD.•Oxidative stress and inflammatory response are important factors in liver injury•The reduction of arachidonic acid in the liver is a hallmark dysregulation in WD.•The cPLA2 and ALOX12 co-regulate arachidonic acid levels.